A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)

Sponsor
GlaxoSmithKline
Study ID
NCT07602855
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ris-Rez — BIOLOGICAL
    Ris-Rez will be administered
  • Ivonescimab — BIOLOGICAL
    Ivonescimab will be administered

Study Details

This is an early-phase clinical study investigating a new combination treatment, Ris-Rez given with ivonescimab for adults with advanced solid cancers. The study aims to determine: * What dose(s) of Ris-Rez given with ivonescimab is safe and what are the side effects? * How does the body handle the drug(s)? * What dose of Ris-Rez given with ivonescimab may work best and can improve the treatment of cancer?

Key Dates

First listed
May 22, 2026
Start date
Sep 8, 2026
Status verified
May 2026
Primary completion
Jul 5, 2029
Completion
Jan 4, 2030

Study Design

Enrollment
184 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ris-Rez + Ivonescimab

Primary Outcome Measure

Confirmed Objective Response Rate (cORR) [ Time Frame: Up to approximately 143 weeks ]

Central Contacts

Related Studies